CAJ | 학술논문

目的观察自体造血干细胞移植(auto-AHSCT)治疗恶性血液病的疗效.方法 1994年10月至2009年5月采用AHSCT治疗的恶性血液病患者28例,中位年龄30(16～45)岁,其中急性髓细胞白血病(AML)19例,急性淋巴细胞白血病(ALL)4例,恶性淋巴瘤(ML)5例.外周血干细胞的动员均给予粒细胞集落刺激因子(G-CSF)5～10μg/kg.预处理方案主要为美法仑(Mel)140～160 mg/m2+环磷酰胺(CTX)120mg/kg+阿糖胞苷(Ara-C)2g/m2.结果移植相关不良反应低,大部分(26例)患者造血重建快,中性粒细胞(ANC)＞0.5×109/L和Plt＞20×109/L的时间分别为12(8～38)和14(9～128)d,中位随访36(7～68)个月,3年无病存活19例(68%),死亡9例(32%)[其中7例(25%)死于移植复发,2例(7%)死于移植后并发症].结论 AHSCT是一种治疗恶性血液病安全有效的方法.
목적 관찰자체조혈간세포이식(auto-AHSCT)치료악성혈액병적료효.방법 1994년10월지2009년5월채용AHSCT치료적악성혈액병환자28례,중위년령30(16～45)세,기중급성수세포백혈병(AML)19례,급성림파세포백혈병(ALL)4례,악성림파류(ML)5례.외주혈간세포적동원균급여립세포집락자격인자(G-CSF)5～10μg/kg.예처리방안주요위미법륜(Mel)140～160 mg/m2+배린선알(CTX)120mg/kg+아당포감(Ara-C)2g/m2.결과 이식상관불량반응저,대부분(26례)환자조혈중건쾌,중성립세포(ANC)＞0.5×109/L화Plt＞20×109/L적시간분별위12(8～38)화14(9～128)d,중위수방36(7～68)개월,3년무병존활19례(68%),사망9례(32%)[기중7례(25%)사우이식복발,2례(7%)사우이식후병발증].결론 AHSCT시일충치료악성혈액병안전유효적방법.
Objective To observe the efficacy of autologous hematopoietic stem cell transplantation (auto-AHSCT) in treatment of malignant hemopathy. Methods A retrospective study was accomplished on the auto-AHSCT in the treatment of 28 patients with malignant hemopathy from Oct 1994 to May 2009. The median age of the patients was 30 (16-45) years. Among the 28 patients,19 cases were acute myelocytic leukemia (AML),4 cases were acute lymphoblastic leukemia (ALL) and 5 cases were malignant lymphoma (ML). Mobilization of peripheral blood stem cell was recieved by giving granulocyte colony-stimulating factor (G-CSF) 5-10 μg/kg. The patients were pretreated with melphalan (140-160 mg/m2),cyclophosphamide (120 mg/kg) and arabinosylcytosin (2 g/m2). Results Transplant-related side effects was less and the hematologic recovery of most patients(26 cases) was quite rapid. The days to stable neutrophil count of 0.5×109/L and platelet count of 20×109/L were 12(8-38) d and 14(9-128) d,respectively. The median followup duration was 36(7-68) months. 19 cases (68 %) achieved disease-free survival(DFS) and 9 cases (32 %)died in three years. Of the 9 death patients,7 cases (25 %) died of recurrence and 2 cases (7 %) died of posttransplant complications. Conclusion AHSCT is a safe and effective therapy method for malignant hemopathy.